We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Drugs Less Effective Than Lifestyle Modifications in Increasing HDL

By Biotechdaily staff writers
Posted on 05 Sep 2007
A recently published review article suggested that lifestyle modifications were more successful in raising high-density lipoprotein (HDL) levels than most available drug treatments.

Nearly 40% of all heart attacks and related cardiovascular problems occur in individuals with low HDL levels. More...
Those with blood levels of HDL lower than 35 mg/dl (16-18% of men and 3- 6% of women) have eight times the risk of heart disease compared to those with 65 mg/dl or more. Thus, finding drug treatments to raise the level of HDL has become of major interest.

A team of investigators reviewed the literature related to attempts to raise HDL levels and compared results from lifestyle modification (dieting, exercise, etc.) to those from various drug treatments. Results of the review of 31 randomized controlled trials published in the August 15, 2007, issue of the Journal of the American Medical Association revealed that several lifestyle modifications were effective in increasing HDL. Among these lifestyle modifications were weight loss, exercise, smoking cessation, moderate alcohol consumption, and eating fish or taking fish oil to increase intake of omega-3 fatty acids.

As for pharmacologic approaches, the study found that the most effective currently available drug to raise HDL is the vitamin niacin, taken in high doses. "Statins, niacin, and fibrates are available pharmacological agents that increase HDL; however, they may be associated with adverse side effects,” said contributing author Dr. Mehdi Shishehbor from the Cleveland Clinic (OH, USA).

"Despite the recent negative HDL trials, this field is extremely exciting and the pace of discovery is unbelievably fast,” Dr. Shishehbor said. "At least one other drug with a novel mechanism of action is also in trials--and at least three other approaches have led to new drugs in the pipeline.”


Related Links:
Cleveland Clinic

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.